Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer (ASpiRE)
ASpiRE: A Proof-of-mechanism and Proof-of-concept Clinical Trial Evaluating the Safety, Tolerability, Biological and Anti-tumour Activity of Apalutamide With Dual CXCR1 and CXCR2 Blockade by SX-682 for Men Suffering From Metastatic Castration-resistant Prostate Cancer (mCRPC)
Sponsor: Belfast Health and Social Care Trust
Listed as NCT07002320, this observational or N/A phase trial focuses on Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and remains actively recruiting participants. Sponsored by Belfast Health and Social Care Trust, it has been updated 4 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
4 versions recorded-
Apr 16, 2026 — Present [daily]
Recruiting
Phase: PHASE1/PHASE2 → None
-
Jan 2026 — Apr 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2025 — Jan 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE1/PHASE2
First recorded
Apr 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
ASpiRE will investigate the effect of the drug SX-682 in combination with Apalutamide in men suffering from metastatic castration-resistant prostate cancer (mCRPC).
Contact Information
- Belfast Health and Social Care Trust
- Cambridge University Hospitals NHS Foundation Trust
- Institute of Cancer Research, United Kingdom
- Institute of Oncology Research (IOR)
- Janssen Pharmaceutica N.V., Belgium
- Oncology Institute of Southern Switzerland
- Prostate Cancer UK
- Royal Marsden NHS Foundation Trust
- Syntrix Biosystems, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .